Phaseline

Companies › ImStem Biotechnology

ImStem Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IMS001
Human embryonic stem cell-derived mesenchymal stem cell with immunomodulatory properties
–Phase 1Multiple SclerosisDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04956744IMS001Phase 1Multiple SclerosisNeurologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.